192 related articles for article (PubMed ID: 33230247)
1. Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China.
Jiang Z; Shen W; Ying S; Gao Z; He X; Chen R; Xia H; Guo X; Fang Y; Zhang Y; Miao J; Zhou J; Zhang X; Chen J; Lou J
Sci Rep; 2020 Nov; 10(1):20373. PubMed ID: 33230247
[TBL] [Abstract][Full Text] [Related]
2. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
[TBL] [Abstract][Full Text] [Related]
3. Mesothelioma Biomarkers: Discovery in Search of Validation.
Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
Thorac Surg Clin; 2020 Nov; 30(4):395-423. PubMed ID: 33012429
[TBL] [Abstract][Full Text] [Related]
4. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
Wang Y; Jiang Z; Yan J; Ying S
Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
[TBL] [Abstract][Full Text] [Related]
6. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
Kaya H; Demir M; Taylan M; Sezgi C; Tanrikulu AC; Yilmaz S; Bayram M; Kaplan I; Senyigit A
Asian Pac J Cancer Prev; 2015; 16(4):1403-7. PubMed ID: 25743806
[TBL] [Abstract][Full Text] [Related]
7. Fibulin-3 as biomarker of malignant mesothelioma.
Ledda C; Caltabiano R; Vella F; Matera S; Marconi A; Loreto C; Rapisarda V
Biomark Med; 2019 Jul; 13(10):875-886. PubMed ID: 31237454
[TBL] [Abstract][Full Text] [Related]
8. Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
Jiang Z; Ying S; Shen W; He X; Chen J; Xia H; Yu M; Xiao Y; Feng L; Zhu L; Ju L; Guo X; Zhang Y; Shen JW; Tong Y; Zhang X; Lou J
Dis Markers; 2017; 2017():1725354. PubMed ID: 29200597
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
Pei D; Li Y; Liu X; Yan S; Guo X; Xu X; Guo X
Oncotarget; 2017 Feb; 8(8):13030-13038. PubMed ID: 28103581
[TBL] [Abstract][Full Text] [Related]
10. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
11. Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis.
Hassan MH; Abuhamdah S; Abdel-Bary M; Wahman M; Abd-Elhamid TH; Beshay M; Mosallam K; Elsadek BEM
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33226065
[TBL] [Abstract][Full Text] [Related]
12. Fibulin-3 immunoexpression in malignant mesothelioma due to fluoro-edenite: a preliminary report.
Caltabiano R; Loreto C; Vitale E; Matera S; Miozzi E; Migliore M; Angelico G; Tumino R; Ledda C; Rapisarda V
Future Oncol; 2018 Mar; 14(6s):53-57. PubMed ID: 29664355
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
Rrapaj E; Trisolini E; Bertero L; Salvo M; Indellicato R; Andorno S; Garcia-Manteiga JM; Rena O; Boldorini RL
Histopathology; 2018 May; 72(6):1039-1050. PubMed ID: 29356044
[TBL] [Abstract][Full Text] [Related]
14. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
Ren R; Yin P; Zhang Y; Zhou J; Zhou Y; Xu R; Lin H; Huang C
Oncotarget; 2016 Dec; 7(51):84851-84859. PubMed ID: 27769044
[TBL] [Abstract][Full Text] [Related]
16. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis.
Tong JD; Jiao NL; Wang YX; Zhang YW; Han F
Neoplasma; 2011; 58(5):441-8. PubMed ID: 21744999
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.
Driml J; Pulford E; Moffat D; Karapetis C; Kao S; Griggs K; Henderson DW; Klebe S
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27376267
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
